BiPAP ST (Spontaneous-Timed) in India: Clinical Guide & Buyer’s Reference (2026)

BiPAP ST is not the same category of device as the OSA-first APAP that dominates the Indian CPAP market. It is a bilevel device with a backup rate — an algorithm-guaranteed minimum breath count per minute, delivered by the machine if the patient does not trigger a breath on their own. That single feature is what makes ST mode the right therapy for central sleep apnea, neuromuscular disease with respiratory muscle weakness, obesity hypoventilation with hypercapnia, and the narrow range of advanced respiratory failure that is manageable at home but would decompensate on CPAP or standard BiPAP S.

This guide is for patients and prescribers navigating the 2026 Indian BiPAP-ST market. It covers what ST does clinically, when it is indicated over BiPAP S (spontaneous only), the titration reality in India (where the clinical workflow is often limited by lab capacity), and the model-by-model breakdown of ST-capable devices available in the Indian market.

What ST mode actually does

A BiPAP S (spontaneous) device delivers two pressures — a higher IPAP on inspiration, a lower EPAP on expiration — and cycles between them based on patient effort. The patient triggers the device on each inspiration, the device cycles back to EPAP on each expiration, and the difference between IPAP and EPAP (the pressure support) is what the patient feels as assistance. If the patient stops breathing, a pure-S device has no mechanism to restart them — it waits for the next inspiratory effort.

BiPAP ST adds a backup rate (BUR, also written as backup breaths per minute). The clinician sets a minimum respiratory rate — typically 10–16 breaths per minute. If the patient’s spontaneous respiratory rate falls below that threshold, the device delivers a breath at the prescribed IPAP for a defined inspiratory time (Ti), cycles to EPAP, and resumes waiting. The patient’s own triggered breaths continue to cycle normally; the backup rate fires only when the patient does not trigger within the time window.

This is clinically critical for:

• Central sleep apnea (CSA): the brainstem fails to send the drive-to-breathe signal for stretches of time; the patient’s airway is often unobstructed but they simply don’t breathe. Without a backup rate the apnea continues until the patient arouses. With a backup rate the device delivers breaths during the central event and the patient’s gas exchange is maintained.
• Neuromuscular disease (ALS, muscular dystrophy, post-polio, advanced myasthenia): the respiratory drive may be preserved but the muscles cannot generate the effort to produce adequate tidal volume. Backup breaths delivered at the prescribed IPAP support ventilation.
• Obesity hypoventilation syndrome (OHS): sustained daytime hypercapnia in the obese patient often worsens at night; BiPAP-ST with a backup rate prevents the nocturnal hypoventilation that drives the daytime PaCO₂ trajectory (Masa JF et al, Pickwick trial (Lancet 2019)).
• Hypercapnic COPD on home NIV: stable chronic hypercapnic COPD benefits from nocturnal bilevel support with a backup rate; this is a distinct indication from the acute NIV used in hospital exacerbations.
• Post-stroke central apnea and brainstem-related hypoventilation.

When ST is indicated over BiPAP S

The line between BiPAP S and BiPAP ST is drawn by the presence of central events or inadequate spontaneous drive. Specifically:

• Pure obstructive OSA — even severe OSA — is managed by CPAP or auto-bilevel (Auto BiPAP). There is no indication for a backup rate in pure OSA.
• Complex sleep apnea syndrome (CompSAS) — where central events emerge on CPAP therapy — often needs BiPAP-ST or adaptive servo-ventilation (ASV). ASV is the more sophisticated choice where available; BiPAP-ST is a reasonable step-down.
• OHS with hypercapnia — the Pickwickian phenotype — needs ST at minimum, often with volume-assured overlay (TVAPS/AVAPS/iVAPS; see our TVAPS guide).
• Neuromuscular hypoventilation of any cause — ST is the entry-level therapy.
• Home NIV for hypercapnic COPD per the BTS/ATS guidance: ST is appropriate, volume-assured bilevel is preferred if the PaCO₂ is very elevated or hypoventilation is severe (BTS/ATS home NIV statement).

The clinical decision is informed by the patient’s arterial blood gas (ABG), particularly daytime PaCO₂; the polysomnography central-AI count; clinical presentation (morning headaches, daytime hypersomnolence disproportionate to AHI, peripheral edema suggesting cor pulmonale); and underlying disease (COPD, OHS, neuromuscular, cardiac).

Pure-S bilevel therapy is appropriate for patients with severe OSA intolerant of CPAP, in whom the underlying physiology is obstruction and drive is preserved. ST adds the backup rate for patients whose drive is not reliably preserved.

Titration expectations in India

BiPAP-ST titration is where the Indian clinical workflow runs into real limitations. The proper setup requires:

1. Overnight polysomnography confirming the underlying diagnosis (CSA quantification, neuromuscular ventilatory picture, nocturnal hypoventilation severity).
2. Overnight NIV titration on the ST device, establishing IPAP, EPAP, backup rate, Ti min/max, trigger sensitivity, cycle sensitivity, and rise time. The titration targets normalization of events, abolition of hypoventilation (nocturnal transcutaneous CO₂ or overnight pulse oximetry), and patient synchrony with the device.
3. Post-titration ABG or transcutaneous CO₂ measurement to confirm ventilation is adequate on the prescribed settings.

In the Indian context in 2026, Level-III home polysomnography is accessible and routine, but in-lab NIV titration is available in roughly 20–30 sleep-capable centres in the country, concentrated in major metros. Transcutaneous CO₂ monitoring is even more limited — perhaps 10–15 centres have it — which means many Indian NIV titrations rely on overnight pulse oximetry as a proxy for ventilation, which is a degraded signal.

The pragmatic Indian pathway for most non-metro patients:

• Diagnostic PSG confirms the indication (CSA, OHS, neuromuscular, COPD overlap).
• NIV-trained respiratory physician prescribes empiric ST settings — typically IPAP 16–20, EPAP 6–8, backup rate 14, Ti min 0.8s, Ti max 1.5s, rise time 300 ms — based on patient weight, disease, and clinical picture.
• Patient is started on therapy at home, followed by phone consultation and device-downloaded data review at 1 week, 2 weeks, 1 month.
• Settings are adjusted remotely based on residual AHI, leak, synchrony markers, and clinical response.
• In-person re-evaluation with ABG at 4–8 weeks.

This empiric titration pathway is not as clean as an in-lab NIV titration, but it is the clinical reality for most of India. It works adequately in the majority of patients; it fails the small fraction with complex ventilatory mechanics (high-trigger effort with thoracic dystrophy, severe ALS with progressing bulbar dysfunction, chronic hypercapnic COPD with severe gas-trapping) who need specialist titration in a reference centre.

Models offering ST mode in the Indian market

Nine ST-capable devices dominate the 2026 Indian BiPAP-ST market, spanning a price range from ~₹23,000 to ~₹1.4 lakh.

Premium tier: ResMed Lumis and Philips DreamStation

The ResMed Lumis 150 VPAP ST Tripack at ₹63,490 (MRP ₹1,38,000) is the flagship home-NIV ST device in the Indian market. Published specs: iVAPS + S + ST + T + PAC + CPAP modes, 2–25 cmH₂O pressure range, 25 dB sound level, 1.26 kg weight, made-in-Australia turbine, heated humidifier, ClimateLineAir heated tube, TiControl for inspiratory time limits, adjustable trigger and cycle sensitivity, adjustable rise time, Intelligent Backup Rate (iBR — delivers backup breaths only when needed, not unnecessarily during coughs or sighs), VSync leak management, AirView cloud connectivity, 3-year warranty per published product documentation. FDA, CE, FAA per spec sheet.

This is the reference implementation of ST mode in the Indian market. The iVAPS (Intelligent Volume-Assured Pressure Support) overlay makes the Lumis 150 also a TVAPS-capable device (see our TVAPS guide) — one device does both pure ST and volume-assured bilevel at the prescriber’s choice.

The ResMed Lumis 100 VPAP ST at ₹47,900 (MRP ₹1,07,520) is the sibling without iVAPS. Published specs: S + ST + T + PAC + CPAP modes, 2–25 cmH₂O, 25 dB, 1.2 kg, heated humidifier, ClimateLineAir compatible, TiControl, adjustable trigger and cycle sensitivity, rise time, iBR, adaptive humidification, Intelligent User Interface with session sleep reports, FDA/CE/FAA. No cloud connectivity on the 100 model per product listings (Wi-Fi/cellular is not included). For pure ST therapy without volume assurance, this is the cleaner buy and saves ~₹15,000 vs the 150.

The ResMed AirCurve 10 ST was ResMed’s mainstream ST platform for the 2015–2022 period; at ₹67,188 per listing, it is currently listed as Discontinued in Indian channel with the successor being the Lumis 100 VPAP ST. Existing users on the AirCurve 10 ST continue to be supported; new buyers should go to the Lumis 100 or Lumis 150.

The Philips DreamStation BiPAP AVAPS at ₹77,952 (MRP ₹1,42,080) offers CPAP + S + S/T + PC + T + AVAPS modes per published specs. 4–30 cmH₂O pressure range, 26.1 dB, 1.98 kg, USA-made turbine, heated humidifier (optional), heated tube compatible, climate control, Digital Auto-Trak leak algorithm, adjustable trigger and cycle sensitivity, TiControl, rise time, inspiratory time setting, pressure support setting, backup rate, central apnea detection, FAA-approved. This is the Philips premium ST device with AVAPS (volume assurance) included.

The higher pressure range (up to 30 cmH₂O) and the broader mode set make the DreamStation AVAPS the choice for patients whose clinical picture is heading toward home ventilator territory — higher IPAP requirement, severe hypercapnia, higher pressure support levels. See our TVAPS guide for the volume-assurance discussion.

Mid-tier: BMC and BPL

The BMC G3 B30VT BiPAP at ₹39,744 (MRP ₹48,000) delivers CPAP + S + T + ST modes per published specs. 4–30 cmH₂O pressure range, 26 dB, 1.7 kg, China-made turbine, heated humidifier, heated-tube compatible, adjustable trigger and cycle sensitivity, TiControl, rise time, Ti setting, backup rate, central apnea detection, altitude compensation, SD-card data, iCode compliance reporting via QR code. 2-year warranty.

At this price, the G3 B30VT is genuinely differentiated — a functional ST-mode BiPAP for under ₹40,000 is a price point that ResMed and Philips do not reach. The B30VT also offers VAT (volume-assurance — BMC’s term for their TVAPS equivalent), which the “VT” in the model designation indicates. For OHS or neuromuscular patients who need ST-with-volume-assurance and are priced out of the Lumis 150 or DreamStation AVAPS, the G3 B30VT is a legitimate option.

The BMC RESmart GII Y30T BiPAP at ₹23,440 (MRP ₹33,600) offers CPAP + S + S/T + T modes. 4–30 cmH₂O pressure range, 30 dB, 2.5 kg, heated humidifier, adjustable trigger and cycle sensitivity, Ti Control, rise time, iCode compliance, 2-year warranty. At this price it is the entry floor of the ST category. The tradeoffs — heavier, noisier, thinner data platform — are real. For cost-constrained patients with stable ST indications it is defensible.

The BMC RESmart GII BiPAP Y25T at ₹25,823 (MRP ₹62,400) is similar but with 4–25 cmH₂O pressure range.

The BPL LifePAP 25STA BiPAP with Auto-EPAP at ₹70,080 (MRP ₹97,920) offers eVAPS + S + T + ST + CPAP + AutoEPAP modes per published specs. 4–25 cmH₂O, 28 dB, 1.55 kg, Indian-manufactured, heated humidifier, adjustable trigger and cycle sensitivity, TiControl, rise time, Ti setting, pressure support setting, backup rate, 2-year warranty. eVAPS is BPL’s volume-assurance implementation; AutoEPAP is auto-titrating expiratory pressure for OSA component management. A well-featured Indian-manufactured device at this price point with genuine volume-assurance capability.

Indian-channel: Oxymed and Deckmount

The Oxymed AirSmart BPAP ST with VAPS at ₹37,490 (MRP ₹59,999) delivers S + S/T + CPAP + PC + T + VAT (VAPS) modes per published specs. 4–30 cmH₂O pressure range, 30 dB, 2.0 kg, German turbine per manufacturer brochure, Swiss sensor per manufacturer brochure, heated humidifier, adjustable trigger and cycle sensitivity between levels 1–3, rise time, Ti setting, pressure support setting, backup rate, leak compensation to 60 L/min, SD card + cloud connectivity, 3-year warranty with PAN-India home service. This is the sharpest price-to-feature proposition in the Indian ST-with-VAPS category — a ST-VAPS BiPAP for under ₹40,000 with 3-year home service is a position that imported brands do not match.

The Deckmount VT200 (VAPS) BiPAP at ₹27,552 (MRP ₹72,000) offers CPAP + S + ST + T + PC + VAPS + Auto CPAP modes per published specs. 4–30 cmH₂O pressure range, 28 dB, 1.8 kg, Indian-made turbine per manufacturer brochure, heated humidifier, adjustable trigger and cycle sensitivity, TiControl, rise time, Ti setting, pressure support setting, central apnea detection, altitude compensation, SD-card data + QR compliance codes. A very aggressive price for VAT-capable ST therapy; Indian-manufacture service reachability is the main tradeoff.

Home Medix HM-BV-30 S/T

The Home Medix HM-BV-30 S/T is a bilevel platform in the domestic-manufacture tier with published ST + AVAPS capability in manufacturer brochures. The device is reviewed on its own merits against the comparable BMC G3 B30VT and Oxymed AirSmart BPAP ST tier. Typical configuration and pricing place it in the ₹35,000–₹45,000 bracket per manufacturer listings; buyers should verify current specs and warranty directly.

Prescription nuances to know

Five things that trip up Indian ST buyers and prescribers:

1. The backup rate is load-bearing. The backup rate is not a ramp-up feature or a comfort tweak; it is the reason the device is an ST and not an S. Prescribers who set backup rate too low (8–10 bpm) on a patient with CSA often under-support ventilation; prescribers who set it too high (20+ bpm) often fight the patient’s spontaneous rhythm and generate dyssynchrony. Typical home-NIV backup rates are 12–16 bpm.

2. Ti (inspiratory time) limits matter. TiControl on ResMed, Ti setting on BMC/Oxymed/Philips, manages how long the device holds IPAP on a delivered breath. Too short and the patient gets inadequate tidal volume; too long and expiratory time gets compressed and gas-trapping worsens. Typical settings: Ti min 0.8s, Ti max 1.5s, with adjustment for underlying disease (shorter Ti for COPD with high expiratory resistance, longer Ti for restrictive neuromuscular disease).

3. Rise time shapes patient tolerance. Rise time is how quickly the device transitions from EPAP to IPAP. Fast rise time (100–200 ms) feels assertive and can be uncomfortable; slow rise time (400–600 ms) feels gentler but may delay adequate inspiration. Typical settings: 300–400 ms, adjusted to patient preference.

4. Trigger and cycle sensitivity affect synchrony. Trigger sensitivity determines how easily the patient triggers IPAP; cycle sensitivity determines when the device transitions back to EPAP. Both are adjustable on the premium devices (Lumis, DreamStation, G3 B30VT) and partially adjustable on lower-tier devices. Mis-set trigger/cycle is the most common cause of patient-ventilator dyssynchrony and of poor tolerance of ST therapy.

5. Mask-fit and leak management are harder on ST than on CPAP. ST pressures (IPAP often 14–20 cmH₂O) are higher than APAP averages (P95 often 10–13). Higher pressure means more leak, which triggers trigger dysfunction, which triggers dyssynchrony. A full-face mask is usually preferred over nasal or nasal-pillow for ST therapy, and the dealer’s mask-fit expertise matters more for ST than for APAP.

Final recommendation

For CSA, complex sleep apnea, or OHS with moderate hypercapnia, the ResMed Lumis 100 VPAP ST at ₹47,900 is the clean mid-premium choice — mature ST implementation, iBR intelligent backup rate, TiControl, strong AirView data platform (on the 150 variant). Step up to the Lumis 150 VPAP ST Tripack at ₹63,490 if iVAPS (volume assurance) is clinically needed.

For severe OHS or hypercapnic COPD on home NIV requiring higher IPAP and volume assurance, the Philips DreamStation BiPAP AVAPS at ₹77,952 (4–30 cmH₂O pressure range) or the Lumis 150 with iVAPS are the appropriate devices. See our TVAPS guide for the volume-assurance choice.

For cost-constrained ST prescriptions where the clinical picture is stable, the Oxymed AirSmart BPAP ST with VAPS at ₹37,490 delivers ST + VAPS with 3-year PAN-India home service — a genuinely differentiated price-to-feature position.

For ST with volume assurance at the price floor, the BMC G3 B30VT at ₹39,744 or the Deckmount VT200 at ₹27,552 are the price-aggressive options. The tradeoffs in algorithm sophistication, data platform, and service reachability are real but can be acceptable depending on the clinical picture.

For Indian-manufactured ST therapy with domestic service, the BPL LifePAP 25STA at ₹70,080 offers eVAPS volume assurance and AutoEPAP in an Indian-manufactured unit.

Patients with ST indications should not compromise on backup-rate implementation quality or on prescriber access for settings adjustment. The device is half the problem; the prescribing and titration workflow is the other half. See also our Auto BiPAP ST guide for the dynamic-settings alternative and the TVAPS explainer for volume-assured bilevel.